Arancibia Sergio, Espinoza Cecilia, Salazar Fabián, Del Campo Miguel, Tampe Ricardo, Zhong Ta-Ying, De Ioannes Pablo, Moltedo Bruno, Ferreira Jorge, Lavelle Ed C, Manubens Augusto, De Ioannes Alfredo E, Becker María Inés
Fundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Clinical & Molecular Pharmacology Program, Instituto de Ciencias Biomédicas (ICBM), Universidad de Chile, Santiago, Chile.
PLoS One. 2014 Jan 23;9(1):e87240. doi: 10.1371/journal.pone.0087240. eCollection 2014.
Hemocyanins, the huge oxygen-transporting glycoproteins of some mollusks, are used as immunomodulatory proteins with proven anti-cancer properties. The biodiversity of hemocyanins has promoted interest in identifying new anti-cancer candidates with improved immunological properties. Hemocyanins promote Th1 responses without known side effects, which make them ideal for long-term sustained treatment of cancer. In this study, we evaluated a novel hemocyanin from the limpet/gastropod Fissurella latimarginata (FLH). This protein has the typical hollow, cylindrical structure of other known hemocyanins, such as the keyhole limpet hemocyanin (KLH) and the Concholepas hemocyanin (CCH). FLH, like the KLH isoforms, is composed of a single type of polypeptide with exposed N- and O-linked oligosaccharides. However, its immunogenicity was significantly greater than that of KLH and CCH, as FLH induced a stronger humoral immune response and had more potent anti-tumor activity, delaying tumor growth and increasing the survival of mice challenged with B16F10 melanoma cells, in prophylactic and therapeutic settings. Additionally, FLH-treated mice demonstrated increased IFN-γ production and higher numbers of tumor-infiltrating CD4(+) lymphocytes. Furthermore, in vitro assays demonstrated that FLH, but not CCH or KLH, stimulated the rapid production of pro-inflammatory cytokines (IL-6, IL-12, IL-23 and TNF-α) by dendritic cells, triggering a pro-inflammatory milieu that may explain its enhanced immunological activity. Moreover, this effect was abolished when deglycosylated FLH was used, suggesting that carbohydrates play a crucial role in the innate immune recognition of this protein. Altogether, our data demonstrate that FLH possesses increased anti-tumor activity in part because it activates a more potent innate immune response in comparison to other known hemocyanins. In conclusion, FLH is a potential new marine adjuvant for immunization and possible cancer immunotherapy.
血蓝蛋白是一些软体动物中巨大的氧运输糖蛋白,被用作具有已证实抗癌特性的免疫调节蛋白。血蓝蛋白的生物多样性激发了人们对鉴定具有改善免疫特性的新抗癌候选物的兴趣。血蓝蛋白可促进Th1反应且无已知副作用,这使其成为癌症长期持续治疗的理想选择。在本研究中,我们评估了一种来自帽贝/腹足纲动物宽边帽贝(FLH)的新型血蓝蛋白。这种蛋白质具有其他已知血蓝蛋白典型的中空圆柱形结构,如钥孔血蓝蛋白(KLH)和海螺血蓝蛋白(CCH)。与KLH亚型一样,FLH由单一类型的多肽组成,带有暴露的N-连接和O-连接寡糖。然而,其免疫原性明显高于KLH和CCH,因为FLH诱导了更强的体液免疫反应且具有更强的抗肿瘤活性,在预防和治疗环境中均可延迟肿瘤生长并提高接种B16F10黑色素瘤细胞的小鼠的存活率。此外,经FLH处理的小鼠表现出IFN-γ产生增加以及肿瘤浸润CD4(+)淋巴细胞数量增多。此外,体外试验表明,FLH而非CCH或KLH可刺激树突状细胞快速产生促炎细胞因子(IL-6、IL-12、IL-23和TNF-α),引发一种促炎环境,这可能解释了其增强的免疫活性。而且,当使用去糖基化的FLH时,这种效应消失,表明碳水化合物在该蛋白的天然免疫识别中起关键作用。总之,我们的数据表明,FLH具有增强的抗肿瘤活性,部分原因是与其他已知血蓝蛋白相比,它激活了更强的天然免疫反应。总之,FLH是一种潜在的新型海洋免疫佐剂,可用于免疫接种和可能的癌症免疫治疗。